AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Treatment or Prevention
2027383 a utility patent covering Ampligen (rintatolimod) and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.
- 2027383 a utility patent covering Ampligen (rintatolimod) and other AIM developed dsRNA products for use in the prevention or treatment of COVID-19, with a base patent term extending until 2041.
- Ampligen is AIMs RNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.
- In another patent embodiment, the therapeutic double-stranded RNA product may be one or more of a number of therapeutic double-stranded RNA (tdsRNA) developed by AIM.
- National patent application filings based on these PCTs, entitled to claim priority from the provisional patent applications, are ongoing.